Table 5. Survival outcomes.
| Outcomes | EP | TPT | Total (N=30) | |||
|---|---|---|---|---|---|---|
| First line (n=24) | ≥2 lines (n=2) | Total (N=26) | ≥2 lines (n=4) | |||
| PFS, months | ||||||
| Median (95% CI) | 8.4 (7.0–10. 5) | 5.4 (5.1–NR) | 8.2 (7.0–10.5) | 3.5 (0.7–NR) | 7.9 (5.1–9.4) | |
| Range | 1.9–18.0 | 5.1–5.8 | 1.9–18.0 | 0.7–4.9 | 0.7–18.0 | |
| OS, months | ||||||
| Median (95% CI) | 12.3 (8.9–NR) | 13.8 (9.4–NR) | 12.3 (9.4–NR) | 4.2 (0.7–NR) | 11.8 (8.9–NR) | |
| Range | 2.4–18.9 | 9.4–18.2 | 2.4–18.9 | 0.7–13.0 | 0.7–18.9 | |
CI, confidence interval; EP, platinum/etoposide; NR, not reached; N, total number of patients; n, number of patients in a respective category; OS, overall survival; PFS, progression-free survival; TPT, topotecan.